New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:00 EDTAERIAerie Pharmaceuticals shares should be bought ahead of data, says Stifel
After traveling with Aerie's management, Stifel believes there is a good chance that the Phase 2b data for the company's Roclatan will be positive. The firm expects the data to be released in late June/early July, and it recommends buying shares of Aerie ahead of the data release. It keeps a $24 price target and Buy rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:31 EDTAERIRBC Capital to hold a conference
Subscribe for More Information
February 18, 2015
06:04 EDTAERIAerie Pharmaceuticals' Rhopressa shows positive preliminary evidence in glaucoma
Aerie Pharmaceuticals announced potentially breakthrough findings from new preclinical research indicating that Aerie’s lead drug candidate, Rhopressa, may block the effect of fibrosis-promoting proteins on cells of the trabecular meshwork, a tissue that helps maintain normal pressure in the eye. Fibrosis at the trabecular meshwork is associated with elevated intraocular pressure in patients with glaucoma. This is the first study to show that Rhopressa, a novel once-daily, triple-action eye drop that lowers IOP in glaucoma patients, has the potential to modify the course of the disease by arresting fibrosis. Pending successful advancement of the Phase 3 registration studies, three-month efficacy results are expected in the middle of Q2. If the trials are successful, the company expects to submit a New Drug Application filing by mid-2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use